Jervell and Lange-Nielsen Syndrome Type 1 (JLNS1): A Comprehensive Disease Characteristics Report

Disease: Jervell and Lange-Nielsen Syndrome 1 · MONDO: 0024540 · OMIM: #220400 · Category: Mendelian (autosomal recessive channelopathy)

Summary

Jervell and Lange-Nielsen syndrome type 1 (JLNS1) is a rare, severe autosomal recessive cardio-auditory channelopathy caused by biallelic loss-of-function mutations in KCNQ1 (the α-subunit of the slow delayed-rectifier potassium current, I_Ks). KCNQ1 mutations account for roughly 90% of JLNS, with the remainder (JLNS2) caused by biallelic KCNE1 mutations encoding the β-subunit. The syndrome is defined by the combination of profound congenital bilateral sensorineural deafness and extreme QT-interval prolongation (mean QTc ~557 ms; diagnostic threshold >500 ms) with a very high risk of syncope, torsades de pointes, and sudden cardiac death. Prevalence is estimated at 1/1,000,000 to 1/200,000.

The unifying mechanism is loss of the same I_Ks channel in two tissues. In ventricular cardiomyocytes, loss of I_Ks removes the repolarization reserve that shortens the action potential during sympathetic activation, producing marked QT prolongation and adrenergically-triggered arrhythmia. In the cochlea, the KCNQ1/KCNE1 channel sits at the apical membrane of strial marginal cells and vestibular dark cells, where it secretes K⁺ into the endolymph to complete the cochlear K⁺ cycle and maintain the high-K⁺, +80 mV endocochlear potential essential for hearing; its loss collapses endolymph K⁺ secretion and causes deafness. A Kcnq1 knockout mouse faithfully recapitulates the inner-ear pathology. A third, under-recognized arm of the disease is gastrointestinal: the same channel recycles K⁺ across the parietal-cell apical membrane, so its loss causes hypochlorhydria, compensatory hypergastrinemia, gastric mucosal hyperplasia, and secondary iron-deficiency anemia.

Clinically, JLNS1 is one of the most malignant forms of long QT syndrome: 86% of patients have cardiac events, half are symptomatic by age 3, and >25% die suddenly. Beta-blockers are first-line but only partially effective (51% event despite therapy), so high-risk patients (QTc >550 ms, syncope in the first year of life) require left cardiac sympathetic denervation and/or an implantable cardioverter-defibrillator. Deafness is managed with cochlear implantation, with auditory outcomes comparable to non-syndromic deafness provided strict peri-operative cardiac precautions are followed. Emerging KCNQ1 suppression-and-replacement (SupRep) gene therapy offers a mutation-independent, proof-of-concept correction strategy of particular relevance to JLNS1's biallelic-null genotype.

Key Findings

Finding 1 — JLNS1 is an autosomal recessive channelopathy caused by biallelic KCNQ1 mutations (~90% of cases)

JLNS is caused by homozygous or compound heterozygous mutations in KCNQ1 (JLNS1, ~90–90.5% of cases) or KCNE1 (JLNS2), encoding the α- and β-subunits, respectively, of the slow delayed-rectifier potassium current I_Ks. Inheritance is autosomal recessive; heterozygous carriers manifest the milder, dominantly-inherited Romano-Ward LQT1 phenotype. Prevalence is estimated between 1/1,000,000 and 1/200,000 worldwide. KCNE1-associated JLNS2 tends to follow a more benign clinical course than KCNQ1-associated JLNS1.

"Most mutations (90.5%) are on the KCNQ1 gene; mutations on the KCNE1 gene are associated with a more benign course." — PMID: 17646758

"Jervell and Lange-Nielsen syndrome (JLNS) is a rare but severe autosomal recessive disease characterized by profound congenital deafness and a prolonged QTc interval (greater than 500 milliseconds)... The prevalence of JLNS is about 1/1000000 to 1/200000 around the world." — PMID: 32508908

Ontology anchors: Gene KCNQ1 (HGNC:6294), KCNE1 (HGNC:6240); MONDO:0024540; OMIM #220400. GO:0005249 (voltage-gated potassium channel activity); GO:0086003 (cardiac muscle cell contraction); CHEBI:29103 (potassium ion, K⁺).

Finding 2 — JLNS is a severe, early-onset LQTS variant with a high cardiac-event rate and only partial beta-blocker efficacy

In the landmark international registry of 186 JLNS patients (Schwartz/Denjoy et al., 2006), 86% had cardiac events and 50% were symptomatic by age 3, with markedly prolonged repolarization (mean QTc 557 ± 65 ms). Approximately 95% of arrhythmic events were triggered by emotion or exercise (sympathetic activation), consistent with the LQT1 mechanism. QTc >550 ms and a history of syncope in the first year of life are independent predictors of cardiac arrest/sudden death. Beta-blockers, although first-line, provide only partial protection: 51% of patients had events despite therapy and 29% suffered cardiac arrest or sudden death. Females are at somewhat lower risk. More than 25% of JLNS patients die suddenly.

"Most patients (86%) had cardiac events and 50% were symptomatic already by age 3. Their QTc was markedly prolonged (557 +/- 65 ms)." — PMID: 17646758

"A QTc>550 ms and history of syncope during the first year of life are independent predictors of subsequent CA/SD." — PMID: 17646758

"beta-blockers have only partial efficacy as 51% of the patients had events despite therapy and 29% had CA/SD." — PMID: 17646758

The nationwide Spanish paediatric LQTS registry (371 children) corroborates this risk profile: major arrhythmic events clustered in "high-risk genotypes" — explicitly including Jervell-Lange-Nielsen — and in children with QTc ≥550 ms or very early (fetal/neonatal) presentation (PMID: 42466893).

Ontology anchors: HP:0001657 (Prolonged QT interval); HP:0004308 (Ventricular arrhythmia / torsade de pointes); HP:0001279 (Syncope); HP:0001645 (Sudden cardiac death); HP:0001695 (Cardiac arrest).

Finding 3 — Mechanism: loss of KCNQ1/KCNE1 I_Ks abolishes marginal-cell K⁺ secretion into endolymph, causing deafness

The KCNQ1/KCNE1 channel is expressed at the apical membrane of strial marginal cells in the cochlea and vestibular dark cells, where it secretes K⁺ into the endolymph. This step completes the cochlear K⁺ recycling cycle required to maintain the high-K⁺, +80 mV endolymph and endocochlear potential (EP) that drives sensory hair-cell mechanotransduction. An additional KCNQ1/KCNE1-mediated K⁺-diffusion potential contributes to EP formation within the stria vascularis. Loss of this channel collapses endolymph K⁺ secretion, producing profound congenital sensorineural deafness.

"Deafness results also from mutations of KCNQ1 or KCNE1, subunits of a K(+) channel that carries K(+) from strial marginal cells and vestibular dark cells into endolymph." — PMID: 12097719

"An additional K(+)-diffusion potential formed by KCNQ1/KCNE1-K" — PMID: 20012478

The detailed K⁺ cycle (from PMID: 12031509) situates KCNQ1/KCNE1 as the final apical secretory step: K⁺ enters the strial marginal cell basolaterally via SLC12A2 (NKCC1) and Na⁺/K⁺-ATPase, then exits apically into endolymph via KCNQ1/KCNE1, "which concludes the cochlear cycle." The same architecture operates in the vestibular labyrinth via dark cells, explaining associated vestibular dysfunction.

Ontology anchors: UBERON:0002215 (stria vascularis); UBERON:0002227 (cochlea); UBERON:0007499 (endolymph); CL:0000710 (marginal cell of stria vascularis); GO:0071805 (potassium ion transmembrane transport); GO:0042472 (inner ear morphogenesis). HP:0000407 (Sensorineural hearing impairment); HP:0000365 (Hearing impairment).

Finding 4 — The Kcnq1 knockout mouse recapitulates JLNS inner-ear pathology

Kcnq1 (Kvlqt1) knockout mice are deaf and display circling behavior (vestibular dysfunction). Temporal-bone histopathology reveals marked atrophy of the stria vascularis, contraction/collapse of the endolymphatic compartments, complete degeneration of the organ of Corti, and secondary spiral-ganglion degeneration — findings that parallel human JLNS temporal-bone pathology and reflect disturbed endolymph production by the stria vascularis.

"Kcnq1 knockout mice were deaf and demonstrated circling behavior. They exhibited a marked atrophy of the stria vascularis, contraction of the endolymphatic compartments, and collapse and adhesion of surrounding membranes. There was a complete degeneration of the organ of Corti and an associated degeneration of the spiral ganglion." — PMID: 15891643

Ontology anchors: NCBITaxon:10090 (Mus musculus); model gene Kcnq1 (NCBI Gene ID 16535). UBERON:0002365 (organ of Corti); UBERON:0002228 (spiral ganglion).

Finding 5 — Management combines cardiac risk reduction with cochlear implantation

Cardiac management centers on beta-blockers as first-line therapy (partial protection only), escalating in high-risk patients (QTc >550 ms, syncope in the first year, aborted arrest) to ICD implantation and/or left cardiac sympathetic denervation (LCSD), alongside strict avoidance of QT-prolonging drugs and sympathetic triggers. Atrial pacing combined with beta-blockade has been proposed for selected young high-risk patients (PMID: 27451284). Cochlear implantation is the standard hearing rehabilitation and yields auditory/language outcomes not worse than in non-syndromic sensorineural deafness, provided cardiac events are controlled and strict peri-operative precautions are used (beta-blockade, avoidance of sympathetic stimulation and QT-prolonging drugs, defibrillator standby, magnesium). Importantly, LQTS/JLNS syncope can be misdiagnosed as epilepsy, delaying correct therapy.

"Fatal Arrhythmias were encountered intra-operatively in five patients which was treated with cardiac pacing." — PMID: 31846911

"The auditory and language outcome after cochlear implantation in this syndrome is not worse than those in patients with non-syndromic sensorineural deafness." — PMID: 18805595

"Current treatment strategies include high doses of beta-blocker medication, left cardiac sympathetic denervation, and ICD placement, which is challenging in young children." — PMID: 27451284

Ontology anchors (NCIT): Beta-adrenergic blocker therapy (propranolol, nadolol); Implantable cardioverter-defibrillator; Left cardiac sympathetic denervation (sympathectomy); Cochlear implantation.

Finding 6 — Heterozygous carriers have milder LQT1; a common founder allele (R518X) exists

Heterozygous carriers of JLNS-causing KCNQ1 variants show a substantially milder phenotype than homozygous JLNS patients, illustrating a gene-dosage effect. In a genotype-stratified cohort, mean QTc was 551 ± 54 ms in JLNS homozygotes vs 441 ± 32 ms in heterozygous-JLNS carriers and 467 ± 36 ms in heterozygous non-JLNS carriers. The recessive JLNS phenotype (deafness + long QTc + ~47% cumulative aborted cardiac arrest) contrasts starkly with the benign dominant LQT1 phenotype of heterozygotes (QTc ~462 ms, ~1% arrest). The nonsense variant p.R518X (c.1552C>T) in KCNQ1 is a common founder allele that causes JLNS when biallelic and LQT1 when heterozygous; in Sweden it is an old founder mutation (~28 generations) with heterozygote prevalence ~1:2,000–4,000, clustering geographically. Consanguinity contributes to JLNS in inbred families.

"the mean QTc was 551 ± 54 ms for JLNS, 441 ± 32 ms for HTZ-JLNS, and 467 ± 36 ms for HTZ-Non-JLNS" — PMID: 38825991

"The R518X/KCNQ1 mutation is a common cause of autosomal recessive (Jervell and Lange Nielsen Syndrome- JLNS) and autosomal dominant long QT syndrome (LQTS) worldwide." — PMID: 24552659

"Clinical phenotype ranged from expectedly severe in JLNS to surprisingly benign in LQTS (QTc 576 ± 61 ms vs. 462 ± 34 ms, cumulative incidence of (aborted) cardiac arrest 47% vs. 1%" — PMID: 24552659

Variant nomenclature: KCNQ1 p.Arg518* (R518X), c.1552C>T — nonsense (loss-of-function), Pathogenic. At least one highly inbred family displayed apparent pseudo-dominant transmission with a milder phenotype and hearing/QT severity correlating (PMID: 23668803).

Finding 7 — JLNS has an extra-cardiac gastrointestinal phenotype: hypochlorhydria, hypergastrinemia, and iron-deficiency anemia

In a Swedish cohort of 14 patients with biallelic KCNQ1 mutations, a history of iron-deficiency anemia was present in 12/14 and subjective GI symptoms in 13/14. Objective findings included elevated gastrin (7/9), elevated pepsinogen (6/7), elevated fecal calprotectin (9/9), and gastric mucosal hyperplasia/dysplasia (3/5 endoscoped). Elevated gastrin correlated significantly with iron deficiency/anemia (p = 0.039). KCNQ1 is essential for gastric acid secretion, recycling K⁺ across the parietal-cell apical membrane to supply the H⁺/K⁺-ATPase; its loss causes hypochlorhydria → impaired dietary iron absorption → iron-deficiency anemia, with compensatory hypergastrinemia that constitutes a potential long-term gastric-cancer risk factor.

"A history of iron-deficiency anaemia in 12 of 14 patients and subjective gastrointestinal symptoms in 13 of 14 patients was revealed." — PMID: 22805636

"We propose that the Jervell and Lange-Nielsen Syndrome phenotypically includes gastrointestinal symptoms/signs and secondary iron-deficiency anaemia owing to hypochlorhydria on the basis of KCNQ1 mutations. The resultant elevated gastrin level is a potential risk factor for later gastrointestinal cancer." — PMID: 22805636

Ontology anchors: HP:0001891 (Iron deficiency anemia); HP:0011473 (Achlorhydria); HP:0003637 (Hypergastrinemia); UBERON:0000945 (stomach); CL:0000162 (parietal cell); GO:0030007 (intracellular potassium ion homeostasis); CHEBI:29103 (potassium ion). Body system: digestive/gastrointestinal (UBERON:0001007).

Finding 8 — I_Ks is a multi-subunit regulated complex; patient iPSC-cardiomyocytes recapitulate LQT1 and reveal therapeutic limits for null-I_Ks JLNS

The I_Ks channel complex is built from Kv7.1 (KCNQ1) co-assembled with the β-subunit KCNE1, plus accessory regulators PIP2, calmodulin, and yotiao (AKAP9). This regulatory flexibility lets one channel serve both cardiac repolarization and endolymph K⁺ maintenance. Patient-derived iPSC-cardiomyocytes from LQT1/KCNQ1 carriers reproduce the disease: markedly prolonged action-potential duration (APD) due to reduced KCNQ1-mediated I_Ks, with some mutations (e.g., R190Q, M437V) acting via dominant-negative trafficking defects. The NOS1AP modifier locus interacts with prolonged repolarization to modulate arrhythmia risk and penetrance. Critically, I_Ks-activator compounds shorten APD in LQT2 but not LQT1, because LQT1/JLNS I_Ks is intrinsically impaired — implying that channel-activator strategies have limited utility when I_Ks is biallelically null, as in JLNS1.

"The IKs channel complex is formed by the co-assembly of Kv7.1 (KCNQ1), a voltage-gated potassium channel, with its β-subunit, KCNE1 and the association of numerous accessory regulatory molecules such as PIP2, calmodulin, and yotiao." — PMID: 32581825

"The duration of the action potential was markedly prolonged in 'ventricular' and 'atrial' cells derived from patients with long-QT syndrome type 1, as compared with cells from control subjects." — PMID: 20660394

"DHA-gly shortened APD in vitro and QT interval ex vivo in WT and LQT2 rabbits, but not in LQT1" — PMID: 40794559

Additional supporting model data: iPSC-CM from an M437V KCNQ1 patient exhibited APD prolongation from reduced I_Ks (PMID: 31245483); human iPSC-CM engineered heart tissue has a low repolarization reserve making it a sensitive QT/arrhythmia test system (PMID: 29925535); NOS1AP minor alleles associate with NOS1 loss-of-function that aggravates the arrhythmia phenotype in prolonged-repolarization syndromes (PMID: 32061134).

Ontology anchors: GO:0086089 (voltage-gated potassium channel activity involved in cardiac repolarization); GO:1990573 (potassium ion import across plasma membrane); regulators AKAP9/yotiao, CALM1 (calmodulin); PIP2 (phosphatidylinositol 4,5-bisphosphate). Model: hiPSC-cardiomyocyte.

Finding 9 — KCNQ1 suppression-and-replacement (SupRep) gene therapy is a mutation-independent proof-of-concept for LQT1/JLNS1

A dual-component KCNQ1 "suppression-and-replacement" (SupRep) gene therapy achieves mutation-independent suppression of endogenous KCNQ1 (via shRNA) combined with delivery of an shRNA-immune replacement KCNQ1 cDNA. In TSA201 cells and LQT1 patient iPSC-cardiomyocytes, it corrected the prolonged action-potential/QT phenotype — the first proof-of-principle gene therapy for complete correction of long QT syndrome type 1. Because it is mutation-independent, a single construct could in principle treat any KCNQ1 genotype, including the biallelic null alleles of JLNS1 — an important conceptual advance, since channel-activator drugs cannot rescue a null channel.

"This study provides the first proof-of-principle gene therapy for complete correction of long QT syndrome." — PMID: 33504163

Mechanistic Model / Interpretation

Ordered causal chain (initiating lesion → clinical manifestation)

Biallelic loss-of-function mutation in KCNQ1 (e.g., R518X; homozygous/compound het)
        │  leads to
        ▼
Absent or non-functional Kv7.1 α-subunit → failure to form functional KCNQ1/KCNE1 IKs channel
        │  results in
        ▼
Loss of the slow delayed-rectifier K+ current (IKs) in multiple K+-transporting epithelia/myocytes
        │
        ├──[CARDIAC BRANCH]──────────────────────────────────────────────┐
        │  Loss of IKs removes repolarization reserve in ventricular      │
        │  cardiomyocytes → prolonged action-potential duration →         │
        │  QT prolongation (QTc ~557 ms). Under sympathetic activation    │
        │  (emotion/exercise, ~95% of triggers), inadequate IKs upregulation
        │  → early afterdepolarizations → torsades de pointes →           │
        │  syncope / cardiac arrest / sudden death (>25%).                │
        │                                                                 │
        ├──[COCHLEAR BRANCH]─────────────────────────────────────────────┤
        │  Loss of apical KCNQ1/KCNE1 in strial marginal cells &          │
        │  vestibular dark cells → failure of K+ secretion into endolymph │
        │  → collapse of K+-rich endolymph & +80 mV endocochlear potential│
        │  → loss of hair-cell mechanotransduction driving force →        │
        │  (developmentally) strial atrophy, endolymphatic collapse,      │
        │  organ of Corti degeneration → profound congenital deafness     │
        │  (+ vestibular dysfunction).                                    │
        │                                                                 │
        └──[GASTRIC BRANCH]──────────────────────────────────────────────┘
           Loss of parietal-cell apical KCNQ1 K+ recycling → impaired
           H+/K+-ATPase-driven acid secretion → hypochlorhydria →
           (a) impaired iron absorption → iron-deficiency anemia
           (b) compensatory hypergastrinemia → gastric mucosal
               hyperplasia/dysplasia → potential long-term cancer risk.

The elegance of JLNS1's pathophysiology is that a single molecular lesion — loss of one K⁺ channel — produces a multi-organ syndrome because KCNQ1/KCNE1 performs the same biophysical job (K⁺ efflux/recycling) in three different epithelia. Upstream is the genetic lesion and channel loss; downstream are the tissue-specific consequences. The cardiac and cochlear arms are the classic defining dyad; the gastric arm is a more recently characterized, under-recognized systemic extension. The cardiac arm is specifically an adrenergic/gene–environment phenotype: I_Ks is the current the healthy heart recruits (via β-adrenergic/PKA signaling anchored by yotiao/AKAP9) to shorten repolarization during sympathetic drive; without it, sympathetic stress becomes dangerous, which is why ~95% of events are triggered by emotion or exercise.

Comparison of phenotypic arms

Genotype–phenotype and dosage

Section-by-Section Reference Compilation

1. Disease Information

JLNS1 is an autosomal recessive cardio-auditory syndrome (deafness + long QT). Identifiers: MONDO:0024540; OMIM #220400; Orphanet ORPHA:90647; ICD-10 I45.81 (long QT syndrome); MeSH D029593 (Jervell-Lange Nielsen Syndrome). Synonyms: Jervell and Lange-Nielsen syndrome; cardioauditory syndrome of Jervell and Lange-Nielsen; surdo-cardiac syndrome; long QT syndrome with deafness. Information is derived predominantly from aggregated disease-level resources (international LQTS registries, OMIM, Orphanet) and case series rather than individual EHR.

2. Etiology

Primary cause is genetic — biallelic LOF mutations in KCNQ1 (JLNS1) or KCNE1 (JLNS2) (Findings 1, 6). No infectious or purely environmental cause. Genetic risk factors: the causal variants; founder alleles (R518X) and consanguinity increase incidence in specific populations. Modifiers: NOS1AP polymorphisms interact with prolonged repolarization to modulate arrhythmia penetrance (PMID: 32061134). Acquired arrhythmia multipliers (triggers, not disease cause): QT-prolonging drugs, sympathetic activation (emotion, exercise, sudden auditory stimuli), electrolyte disturbance. Protective factors: female sex confers lower cardiac risk; strict trigger avoidance and beta-blockade reduce events. Gene–environment interaction: the phenotype is fundamentally adrenergic — I_Ks loss becomes clinically dangerous under sympathetic stress (95% of events triggered by emotion/exercise).

3. Phenotypes

Core phenotypes: profound bilateral congenital sensorineural deafness (HP:0000407; essentially fully penetrant, congenital, stable, severe) and prolonged QT interval / torsades / syncope / sudden death (HP:0001657, HP:0004308, HP:0001279, HP:0001645; onset neonatal–early childhood, 50% symptomatic by age 3, severe, episodic-triggered). Extra-cardiac: iron-deficiency anemia (HP:0001891, ~85%), hypochlorhydria/hypergastrinemia, GI symptoms; vestibular dysfunction (delayed motor milestones from balance impairment). Quality-of-life impact is substantial: lifelong deafness plus activity restriction (avoidance of competitive sport/emotional stress), device dependence (ICD/cochlear implant), and the psychological burden of sudden-death risk.

4. Genetic / Molecular Information

Causal genes: KCNQ1 (11p15.5–15.4; OMIM 607542; HGNC:6294) — ~90%; KCNE1 (21q22.12; OMIM 176261; HGNC:6240) — JLNS2. Variant types: nonsense (e.g., R518X), missense, frameshift, splice-site — predominantly loss-of-function; JLNS requires biallelic hits. Functional consequence: loss of function / loss of I_Ks; some heterozygous LQT1 alleles act dominant-negative (trafficking defects, e.g., R190Q, M437V). Origin: germline. Allele frequency: individual pathogenic alleles are rare in gnomAD; founder alleles are regionally enriched. Modifier: NOS1AP. Epigenetic/chromosomal contributions: none established.

5. Environmental Information

No toxin, radiation, pollution, occupational, or infectious cause. Relevant acquired arrhythmia modifiers: QT-prolonging medications, hypokalemia/hypomagnesemia, sympathetic triggers. Lifestyle: avoidance of strenuous/competitive exercise and emotional stressors is recommended.

6. Mechanism / Pathophysiology

See the ordered causal chain and Mechanistic Model above (Findings 3, 4, 7, 8). Molecular pathway: β-adrenergic (PKA/cAMP) → yotiao/AKAP9-anchored phosphorylation normally augments I_Ks; channel loss removes this adaptive repolarization response. Cellular processes: ion transport, membrane repolarization, endolymph homeostasis, acid secretion. Protein dysfunction: loss/trafficking failure of Kv7.1. Cell types: ventricular cardiomyocytes, strial marginal cells, vestibular dark cells, gastric parietal cells.

7. Anatomical Structures Affected

Primary organs: heart (ventricular myocardium/conduction — UBERON:0000948, UBERON:0002349) and inner ear (cochlea/stria vascularis UBERON:0002227/0002215; vestibular labyrinth). Secondary: stomach (UBERON:0000945), hematologic system (secondary anemia), brain (secondary hypoxic-ischemic injury from arrests). Body systems: cardiovascular, nervous/sensory (auditory + vestibular), digestive. Subcellular: apical plasma membrane of epithelial cells (GO:0016324); cardiomyocyte sarcolemma. Lateralization: bilateral (hearing) and systemic (cardiac).

8. Temporal Development

Onset: deafness is congenital; cardiac events begin in infancy/early childhood (50% symptomatic by age 3; fetal/neonatal bradycardia can be a harbinger of malignant genotype). Course: deafness is stable/non-progressive; the cardiac phenotype is lifelong and episodic, with arrhythmic events triggered by adrenergic stress. Critical period: first year of life — syncope then is a strong predictor of subsequent cardiac arrest/sudden death. Untreated natural history carries very high early mortality.

9. Inheritance and Population

Autosomal recessive. Prevalence 1/1,000,000–1/200,000. Penetrance of deafness essentially complete in biallelic patients; cardiac severity variable/expressivity variable. Founder effects (R518X in Sweden, ~28 generations, carrier ~1:2,000–4,000) and consanguinity raise regional incidence. School-based ECG screening of deaf children found JLNS in ~0.9% (PMID: 34308870). Sex ratio ~equal for the syndrome, but females have lower cardiac-event risk.

10. Diagnostics

ECG (Bazett QTc; diagnostic >500 ms, often >550) with exercise stress testing; audiometry (profound bilateral SNHL). Genetic testing is confirmatory: single-gene KCNQ1/KCNE1 testing, LQTS/hearing-loss gene panels, or WES/WGS. Genetic testing is essential to distinguish true JLNS from the coincidental co-occurrence of independent deafness (e.g., PCDH15) and LQT genes (PMID: 41563185). Supportive: elevated gastrin/pepsinogen/calprotectin and iron studies for the GI arm. Differential diagnosis: Romano-Ward LQTS with unrelated deafness, Pendred syndrome (deafness+goiter), Usher/Waardenburg (deafness without LQT), other LQTS genotypes; seizure disorders (syncope misdiagnosed as epilepsy).

11. Outcome / Prognosis

Malignant without treatment: >25% sudden death; 86% cardiac-event rate; 29% cardiac arrest/SD even on beta-blockers. Prognostic factors: QTc >550 ms, syncope in first year, aborted arrest, male sex, high-risk genotype = worse; female sex, controlled triggers, LCSD/ICD = better. Deafness causes permanent disability mitigated by cochlear implantation. With comprehensive management (beta-blockers + LCSD/ICD + implant), survival and function improve substantially.

12. Treatment

Pharmacotherapy: beta-blockers (propranolol, nadolol) first-line (NCIT: beta-adrenergic blocker therapy); mexiletine adjunct in some LQTS. Device/interventional: ICD; left cardiac sympathetic denervation (thoracoscopic — 73% arrhythmia reduction in ventricular-arrhythmia cohorts, PMID: 24268954); atrial pacing + beta-blockade in selected young patients; catheter ablation of triggering PVCs in refractory storm (PMID: 33040543). Deafness: cochlear implantation. Supportive: iron supplementation for the anemia arm. Experimental/advanced: KCNQ1 SupRep gene therapy (mutation-independent proof-of-concept, PMID: 33504163); note I_Ks-activator drugs fail in LQT1/null-I_Ks (PMID: 40794559).

13. Prevention

No primary prevention of the genetic disease. Genetic counseling and carrier/cascade screening in affected families; prenatal/preimplantation testing feasible. Secondary prevention: ECG screening of congenitally deaf children detects unrecognized JLNS (PMID: 34308870). Tertiary prevention: trigger avoidance (QT-prolonging drugs, competitive sport, sudden loud stimuli), beta-blockade, device therapy, and peri-operative arrhythmia precautions during cochlear implantation.

14. Other Species / Natural Disease

Orthologous gene Kcnq1 in mouse (NCBI Gene 16535, NCBITaxon:10090) and rat. No prominent naturally-occurring companion-animal JLNS equivalent is established; the disease is studied primarily via engineered rodent models. The mechanism (KCNQ1-dependent endolymph K⁺ secretion and cardiac repolarization) is evolutionarily conserved across mammals.

15. Model Organisms

Mouse Kcnq1 knockout — the key model, reproducing deafness, circling/vestibular dysfunction, strial atrophy, and organ-of-Corti degeneration (Finding 4; PMID: 15891643); species differences in ventricular repolarization reserve limit full recapitulation of the human QT phenotype. Human iPSC-derived cardiomyocytes / engineered heart tissue from LQT1/KCNQ1 patients recapitulate APD/QT prolongation and serve as platforms for mechanism and therapy testing (Findings 8, 9; PMID: 20660394, PMID: 31245483, PMID: 29925535). Guinea-pig cardiomyocyte pharmacological LQT1 models are used for modifier (NOS1AP) studies (PMID: 32061134). Rabbit LQT1 models test I_Ks-activator pharmacology (PMID: 40794559).

Evidence Base

Limitations and Knowledge Gaps

1. Rarity limits epidemiology. Prevalence estimates span a five-fold range (1/1,000,000–1/200,000); incidence and geographic/variant distribution data are sparse outside founder populations.
2. GI phenotype based on a single small cohort. The hypochlorhydria/anemia/hypergastrinemia arm rests largely on 14 Swedish patients (PMID: 22805636); the proposed long-term gastric-cancer risk is inferred, not demonstrated longitudinally.
3. Model species differences. Mice have different ventricular repolarization reserve, so the Kcnq1 KO reproduces deafness far better than the human QT/arrhythmia phenotype; iPSC-CMs model the cardiac arm but not the intact organ or the auditory/gastric arms.
4. Therapeutic gap for null I_Ks. Beta-blockers are only partially effective and I_Ks-activators cannot rescue biallelic-null channels; SupRep gene therapy remains pre-clinical (in vitro/iPSC-CM only), with no in vivo JLNS1 efficacy data.
5. Modifier landscape incomplete. Beyond NOS1AP, the genetic/environmental determinants of the wide cardiac-severity variability are not fully mapped.
6. Abstract availability. Several key papers (e.g., 17646758 38825991 27451284 33504163 31846911) had limited/no abstract text available; claims rely on the verified snippets recorded during the investigation.

Proposed Follow-up Experiments / Actions

1. Advance KCNQ1-SupRep toward in vivo proof of concept in a humanized/biallelic-null JLNS1 model (AAV delivery to cardiomyocytes; evaluate QT correction and safety), given that activator drugs cannot rescue null I_Ks.
2. Longitudinal GI surveillance cohort to quantify hypochlorhydria, hypergastrinemia, iron-deficiency anemia frequency, and gastric-neoplasia risk across JLNS1 patients internationally; test iron/gastrin as biomarkers.
3. Multi-organ JLNS1 modeling — inner-ear-specific vs cardiac-specific conditional Kcnq1 knockouts, plus iPSC-derived otic and gastric organoids — to dissect tissue-specific consequences and test correction per arm.
4. Genotype–phenotype and modifier studies in an expanded JLNS registry to identify modifiers (beyond NOS1AP) explaining cardiac-severity variability and refine risk stratification.
5. Prospective ECG screening programs in congenitally deaf children (building on PMID: 34308870) to reduce first-event sudden death through early diagnosis and beta-blockade.
6. Peri-operative protocol standardization for cochlear implantation in LQTS/JLNS (beta-blockade, magnesium, defibrillator standby, pacing readiness), validated across centers.

Report compiled from an autonomous 5-iteration literature-based investigation. Evidence types are labeled human clinical, model organism, or in vitro throughout. All quoted snippets were verified against source abstracts where available.